News

Review: Opioid prescriptions are the work of many physicians


 

FROM JAMA INTERNAL MEDICINE

References

A “broad swath” of Medicare providers wrote scripts for opioids in 2013, contradicting the idea that the overdose epidemic is mainly the work of “small groups of prolific prescribers and corrupt pill mills,” investigators wrote online in JAMA Internal Medicine.

“Contrary to the California workers’ compensation data showing a small subset of prescribers accounting for a disproportionately large percentage of opioid prescribing, Medicare opioid prescribing is distributed across many prescribers and is, if anything, less skewed than all drug prescribing,” said Dr. Jonathan H. Chen of the Veterans Affairs Palo Alto (Calif.) Health Care System, and his associates.

Their study included 808,020 prescribers and almost 1.2 billion Medicare Part D claims worth nearly $81 billion dollars. They focused on schedule II opioid prescriptions containing oxycodone, fentanyl, hydrocodone, morphine, methadone, hydromorphone, oxymorphone, meperidine, codeine, opium, or levorphanol (JAMA Intern Med. 2015 Dec 14. doi: 10.1001/jamainternmed.2015.6662).

Not surprisingly, specialists in pain management, anesthesia, and physical medicine wrote the most prescriptions per provider. But family practitioners, internists, nurse practitioners, and physician assistants wrote 35,268,234 prescriptions – more than all other specialties combined. “The trends hold up across state lines, with negligible geographic variability,” the researchers said.

The findings contradict an analysis of California workers’ compensation data, in which 1% of prescribers accounted for a third of schedule II opioid prescriptions, and 10% of prescribers accounted for 80% of prescriptions, the investigators noted. Nonetheless, 10% of Medicare prescribers in Dr. Chen’s study accounted for 78% of the total cost of opioids, possibly because they were prescribing pricier formulations or higher doses.

Overall, the findings suggest that opioid prescribing is “widespread” and “relatively indifferent to individual physicians, specialty, or region” – and that efforts to stem the tide must be equally broad, the researchers concluded.

Their study was supported by the VA Office of Academic Affiliations, the VA Health Services Research and Development Service, the National Institute of General Medical Sciences, and the Peter F. McManus Charitable Trust. The researchers had no disclosures.

Recommended Reading

EADV: Intralesional therapy for scleroderma dystrophic calcifications
MDedge Rheumatology
Dengue disease is here and U.S. physicians need to get to know it
MDedge Rheumatology
Study finds inaccurate reporting of pain by back pain sufferers
MDedge Rheumatology
Jury still out on cannabinoid therapy for rheumatic diseases
MDedge Rheumatology
ACR: Ozone injections reduce pain and improve function in knee OA
MDedge Rheumatology
FDA approves first naloxone nasal spray for opioid overdose
MDedge Rheumatology
Standing with our patients
MDedge Rheumatology
Naloxone to revive an addict
MDedge Rheumatology
PROMIS physical function domain outperforms in cervical spine patients
MDedge Rheumatology
Functional dependence linked to risk of complications after spine surgery
MDedge Rheumatology